EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy

Rui Li, Dong-Mei Hu, Yong-Li Liu, Wei Zhao, Yu-Xin Zhang, Yi-Qing Qu iD

PLOS Computational Biology · 12.03.2026 · 22 (3) · e1014050

DOI: 10.1371/journal.pcbi.1014050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 12.03.2026. Verfasst von Rui Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pueraria, Insulin-Like Growth Factor Binding Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulation of N6-methyladenosine (m 6 A) modification drives progression in non-small cell lung cancer (NSCLC), yet its interplay with traditional medicine-derived therapeutics remains largely unexplored. We propose a novel strategy that integrates m 6 A-based prognostic subtypes with Pueraria pharmacology to identify prognostic markers and therapeutic targets related to m 6 A regulators for NSCLC treatment. Multi-omics clustering of 1,661 NSCLC samples identified three distinct m 6 A modification patterns. Based on these, a robust 19-gene prognostic signature was constructed via Cox regression and validated in the GSE31210 dataset. This risk model significantly correlated with immune infiltration and patient survival. Furthermore, the expression patterns of these genes were validated via single-cell RNA-sequencing (scRNA-seq) and RT-qPCR in NSCLC cell lines. To identify pharmacological interventions, we intersected the m 6 A prognostic signature with 7,333 NSCLC-related genes and 366 Pueraria targets, revealing IGFBP1 as the core therapeutic nexus. Immunohistochemistry confirmed the expression of IGFBP1 in NSCLC tissues. Molecular docking and 100-ns molecular dynamics (MD) simulations confirmed stable binding of Pueraria compounds to IGFBP1, specifically 7,8,4’-trihydroxyisoflavone (binding energy = -8.3 kcal/mol) and genistein (-7.4 kcal/mol). This study establishes IGFBP1 as a therapeutic nexus connecting m 6 A-driven NSCLC progression and the anti-tumor effects of Pueraria. Our RNA-modification-guided pharmacology approach advances the integration of traditional medicines into precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPuerariaInsulin-Like Growth Factor Binding Protein 1HumansNetwork PharmacologyAdenosineEpigenesis, GeneticMultiomicsCell Line, TumorGene Expression Regulation, NeoplasticPrognosisComputational BiologyRNA Methylation

Substanzen

Insulin-Like Growth Factor Binding Protein 1IGFBP1 protein, humanAdenosineN-methyladenosine

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.

ORCID-Profile: Yi-Qing Qu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, R., Hu, D. M., Liu, Y. L., Zhao, W., Zhang, Y. X., & Qu, Y. Q. (2026). Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy. PLOS Computational Biology, 22(3), e1014050. https://doi.org/10.1371/journal.pcbi.1014050

Vancouver

Li R, Hu DM, Liu YL, Zhao W, Zhang YX, Qu YQ. Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy. PLOS Computational Biology. 2026;22(3):e1014050. doi:10.1371/journal.pcbi.1014050

BibTeX
@article{Li2026,
  author = {Li, Rui and Hu, Dong-Mei and Liu, Yong-Li and Zhao, Wei and Zhang, Yu-Xin and Qu, Yi-Qing},
  title = {Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy},
  journal = {PLOS Computational Biology},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {e1014050},
  doi = {10.1371/journal.pcbi.1014050}
}
Kostenlos starten →